Menu
← Oncology Approval Tracker
FDA DECISION ·
Zepzelca + Tecentriq or Tecentriq Hybreza
lurbinectedin + atezolizumab or atezolizumab and hyaluronidase-tqjs · Jazz Pharmaceuticals and Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As maintenance for adults with extensive-stage SCLC without progression after first-line induction with carboplatin, etoposide, and atezolizumab or atezolizumab and hyaluronidase-tqjs.
LAMPGEN ANALYSIS
Why it matters
IMforte supported adding lurbinectedin to checkpoint therapy as maintenance after a defined induction regimen.
What research teams should watch
Track the final induction assessment, verify the maintenance eligibility window, and coordinate blood count monitoring.
PRIMARY RECORDS